Vaxcyte
NASDAQ: PCVX6 known investors
Find your way into Vaxcyte
449 people in our graph share verified history with the Vaxcyte team — schools, employers, funds. One of them is your warm intro.
Alex Tranunlockedknows Grant Pickering · together at Kleiner Perkins (overlapped)
×10knows the team · via Kleiner Perkins
knows the team · via Georgetown University McDonough School of Business
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.
Founders & leadership
GP
Grant PickeringinCo-Founder, CEO, DirectorFounder of Vaxcyte, which develops vaccines to prevent bacterial infections using a cell-free protein synthesis platform. He has held leadership roles in the development and commercialization of several life science products, including Provenge, Flonase, Victrio, and Zelnate, with experience in biopharmaceutical commercialization, clinical development, fundraising, and corporate development.
Investors · 6
Competitors · 2
by search overlap
Dynavax NASDAQ: DVAX www.dynavax.com43 shared keywordsDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
Vaccinex40 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Companies competing with Vaxcyte for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firmfinance.yahoo.com · Sep 2026
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Knowfinance.yahoo.com · Sep 2026Frequently asked questions
- What does Vaxcyte do?
- Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.
- Who founded Vaxcyte?
- Vaxcyte was founded by Grant Pickering.
- Who are Vaxcyte's investors?
- Vaxcyte's investors include BioRock Ventures, CTI Life Sciences Fund L.P., Foresite Capital, Frazier Life Sciences, Longitude Capital, RA Capital.